Get the Stockscreener App
0.613
7.26%
-0.048
After Hours:
.63
0.017
+2.77%
Scisparc Ltd stock is traded at $0.613, with a volume of 70,385.
It is down -7.26% in the last 24 hours and down -58.01% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.661
Open:
$0.6611
24h Volume:
70,385
Relative Volume:
0.04
Market Cap:
$3.12M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.085
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-7.40%
1M Performance:
-58.01%
6M Performance:
-88.51%
1Y Performance:
+13.79%
1-Day Range:
$0.5933
$0.6611
1-Week Range:
$0.5838
$0.6901
52-Week Range:
$0.226
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.613 | 3.36M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Scisparc Ltd Stock (SPRC) Latest News
Will SciSparc Ltd. stock benefit from infrastructure spendingProduct Launch & High Accuracy Investment Signals - mfd.ru
Can SciSparc Ltd. stock outperform in a bear marketWeekly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
Should you avoid Star Equity Holdings Inc stock right nowMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
SciSparc Shareholders Approve February Governance Agenda - TipRanks
Aug Sentiment: How correlated is SciSparc Ltd to the S P5002025 Earnings Impact & Real-Time Chart Pattern Alerts - baoquankhu1.vn
SciSparc subsidiary receives U.S. patent for antibiotic-enhancing cannabinoid technology - Investing.com Nigeria
SciSparc Subsidiary NeuroThera Wins U.S. Patent for Cannabinoid-Based Antimicrobial Resistance Platform - TipRanks
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome ... - Caledonian Record
Cannabinoid-antibiotic combo boosts MRSA-fighting power in pre-clinical studies - Stock Titan
Ideas Watch: What is the target price for SciSparc Ltd stockJuly 2025 Highlights & Target Return Focused Picks - baoquankhu1.vn
Aug Fed Impact: What is SciSparc Ltds TAM Total Addressable MarketMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Entry Recap: Is SciSparc Ltd backed by strong institutional buyingJuly 2025 Update & AI Enhanced Execution Alerts - baoquankhu1.vn
Market Trends: Is SciSparc Ltd part of any ETFWeekly Risk Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
SciSparc acquires MUSE system IP portfolio to enter GERD device market - Investing.com Australia
SciSparc acquires MUSE system IP portfolio to enter GERD device market By Investing.com - Investing.com South Africa
SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization - TipRanks
SciSparc Acquires Innovative GERD Device IP Portfolio from Xylo Technologies to Target Multi-Billion Dollar Market - Quiver Quantitative
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate ... - Caledonian Record
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization - GlobeNewswire
Big Money Moves: Is Funko Inc part of any ETFJuly 2025 Chart Watch & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Wrap: Should you buy the dip on Rithm Acquisition Corp Debt Equity Composite UnitsWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
SciSparc receives Nasdaq notice over stockholders’ equity shortfall - MSN
Gainers Report: Is SciSparc Ltd backed by strong institutional buyingDollar Strength & AI Driven Price Predictions - baoquankhu1.vn
SPRC Stock Price, Forecast & Analysis | SCISPARC LTD (NASDAQ:SPRC) - Chartmill
Short Covering: What drives SciSparc Ltd.’s stock price2025 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Form 424B5 SciSparc Ltd. - StreetInsider
SciSparc Receives Nasdaq Notice Over Minimum Stockholders’ Equity Non-Compliance - The Globe and Mail
SciSparc Launches $766,170 Registered Direct Share Offering - The Globe and Mail
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc to Acquire Endoscopic Device Patents Targeting $3B Market - Meyka
SciSparc Moves Into Endoscopy With Strategic Patent Deal - Sahm
SciSparc Ltd. (SPRC) stock: dips nearly 12% as company unveils strategic MUSE™ endoscopic technology acquisition - parameter.io
SciSparc Faces Nasdaq Non-Compliance Challenge Over Stockholders’ Equity - StocksToTrade
SciSparc to acquire MUSE endoscopic system patents from Xylo - Investing.com
SciSparc Faces Nasdaq Noncompliance: Struggles Loom - StocksToTrade
SciSparc Signs Agreement To Acquire Patent Portfolio For Endoscopic Technologies; Stock Soars - Nasdaq
SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal - marketscreener.com
SciSparc to Acquire Xylo GERD Device IP in Share-Based Deal, Targeting Global Endoscope Market - TipRanks
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - The Manila Times
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity By Investing.com - Investing.com Nigeria
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity - Investing.com
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - The Manila Times
SciSparc Ltd. Receives Nasdaq Notification of Non-Compliance with Stockholders' Equity Requirement - Quiver Quantitative
Is SciSparc Ltd. stock oversold or undervaluedChart Signals & Low Drawdown Momentum Ideas - Улправда
Breakout Zone: How SciSparc Ltd stock benefits from global expansionJuly 2025 Intraday Action & Growth Focused Investment Plans - Bộ Nội Vụ
Published on: 2026-01-09 12:53:14 - Улправда
Why SciSparc Ltd. stock remains on watchlistsJuly 2025 WrapUp & Growth Focused Stock Reports - Улправда
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):